Antibody for selective inhibition of T-cell responses
US8524234B2 · kind B2 · utility
5Cited by
3References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 5, 2012 |
| Grant date | Sep 3, 2013 |
| Priority date | — |
| Expiry date | Nov 5, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-αβ TCR antibodies and antibody fragments. Anti-αβ TCR antibodies are antibodies which bind to a αβ TCR. Anti-αβ TCR antibodies produced by the hybridoma TOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-αβ TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.